Cornercap Investment Counsel’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Cornercap Investment Counsel’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-43,177	Closed	-$123K	–	548
2024 Q3	$123K	Sell	43,177 -36,046	-45%	-$112K	0.04%	487
2024 Q2	$231K	Sell	79,223 -329	-0.4%	-$900	0.04%	533
2024 Q1	$254K	Hold	79,552	–	–	0.04%	537
2023 Q4	$267K	Sell	79,552 -157	-0.2%	-$404	0.04%	495
2023 Q3	$190K	Sell	79,709 -1,270	-2%	-$2.66K	0.03%	496
2023 Q2	$143K	Buy	80,979 +39,971	+97%	+$102K	0.02%	537
2023 Q1	$126K	Sell	41,008 -25,108	-38%	-$150K	0.02%	531
2022 Q4	$350K	Hold	66,116	–	–	0.06%	458
2022 Q3	$233K	Buy	+66,116	New	+$219K	0.04%	473

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Cornercap Investment Counsel's PSTX Position: Q4 2024 in Review

Cornercap Investment Counsel sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 43,177 shares — an estimated $123K sold.

Cornercap Investment Counsel first reported a position in PSTX in Q3 2022 and held it in 9 quarters. The position peaked at $350K in Q4 2022. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Cornercap Investment Counsel reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Cornercap Investment Counsel sold 43,177 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $123K.
Cornercap Investment Counsel first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 9 quarters.
Cornercap Investment Counsel's Poseida Therapeutics, Inc. Common Stock position peaked at $350K in Q4 2022.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Cornercap Investment Counsel's 13F filing for Q4 2024, filed 12 Feb 2025.